MARKET

THMO

THMO

ThermoGenesis Holdings Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.450
+0.080
+3.39%
After Hours: 2.450 0 -0.01% 16:51 03/05 EST
OPEN
2.400
PREV CLOSE
2.370
HIGH
2.480
LOW
2.160
VOLUME
513.29K
TURNOVER
--
52 WEEK HIGH
14.18
52 WEEK LOW
1.630
MARKET CAP
19.10M
P/E (TTM)
-0.6478
1D
5D
1M
3M
1Y
5Y
ThermoGenesis Holdings Begins a Year of Celebration of its 35th Anniversary in the Cell Banking and Cell Therapy Industry
ThermoGenesis Holdings, Inc. ("ThermoGenesis" or the "Company") (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Company will kick off a year of celebration of its ...
PR Newswire · 02/17 13:30
ThermoGenesis Holdings Launches A GMP Compliant Automated Cell Washing And Reformulation System PXP-LAVARE For CAR-T Manufacturing
ThermoGenesis Holdings Launches a GMP Compliant Automated Cell Washing and Reformulation System -- PXP™-LAVARE -- for CAR-T Manufacturing   RANCHO CORDOVA, Calif., Feb. 3, 2021 /PRNewswire/ --
Benzinga · 02/03 13:40
ThermoGenesis Holdings Launches a GMP Compliant Automated Cell Washing and Reformulation System -- PXP™-LAVARE -- for CAR-T Manufacturing
, /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that it has completed the development process, submitted a Letter to File an...
PR Newswire - PRF · 02/03 13:30
ThermoGenesis Holdings Launches a GMP Compliant Automated Cell Washing and Reformulation System -- PXP-LAVARE -- for CAR-T Manufacturing
ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that it has completed the development process, submitted a Letter to File and updated the devic...
PR Newswire · 02/03 13:30
ThermoGenesis Holdings Launches a GMP Compliant Automated Cell Washing and Reformulation System -- PXP-LAVARE -- for CAR-T Manufacturing
ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that it has completed the development process, submitted a Letter to File and updated the devic...
PR Newswire · 02/03 13:30
GME, AMRS, CLII and HGEN among premarket gainers
Adamis Pharmaceuticals (ADMP) +66% as its epinephrine products added to Walgreens club.Climate Change Crisis Real Impact I Acquisition Corporation (CLII) +48% as EV fast charging company EVgo to go public via SPAC.SCYNEXIS
Seekingalpha · 01/22 13:26
ADiTx Therapeutics, Celsion leads healthcare gainers; Obalon Therapeutics, Cancer Genetics among major losers
Gainers: ADiTx Therapeutics (ADTX) +63%, Celsion (CLSN) +58%, Genetic Technologies (GENE) +39%, Addex Therapeutics (ADXN) +26%, ThermoGenesis Holdings (THMO) +19%.Losers: Obalon Therapeutics (OBLN) -25%, Cancer Genetics (CGIX) -24%, Adamis Pharmaceuticals ...
Seekingalpha · 01/21 15:59
Thermogenesis Holdings to Participate at the H.C. Wainwright BIOCONNECT 2021 Conference
, /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that , Chief Financial Officer, will present a company overview at the H.C. W...
PR Newswire - PRF · 01/07 13:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of THMO. Analyze the recent business situations of ThermoGenesis Holdings Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average THMO stock price target is 8.50 with a high estimate of 8.50 and a low estimate of 8.50.
EPS
Institutional Holdings
Institutions: 29
Institutional Holdings: 312.60K
% Owned: 4.01%
Shares Outstanding: 7.80M
TypeInstitutionsShares
Increased
1
6.90K
New
8
66.10K
Decreased
5
4.34K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Office Equipment
-0.67%
Technology Equipment
+3.30%
Key Executives
Chairman/President/Chief Executive Officer/Director
Xiaochun Xu
Chief Financial Officer/Secretary
Jeffery Cauble
Independent Director
Debra Donaghy
Independent Director
Russell Medford
Independent Director
Joseph Thomis
Independent Director
Mark Westgate
No Data
About THMO
ThermoGenesis Holdings, Inc., formerly Cesca Therapeutics Inc., develops, commercializes and markets a range of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. It offers a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Its CAR-TXpress platform is its cellular processing platform. It offers cell manufacturing tools and services in the global cell and gene therapy market.

Webull offers kinds of Thermogenesis Holdings Inc stock information, including NASDAQ:THMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, THMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading THMO stock methods without spending real money on the virtual paper trading platform.